CAR-T · Chronic disease management · Telemedicine follow-up
Cellular & Advanced Immunotherapy
For lymphoma, paediatric neuroblastoma and medullary thyroid cancer — China's cutting-edge cell therapies and long-arm telemedicine keep patients in remission from home.
Haematological OncologyLymphoma — CAR-T Cell Immunotherapy
China hosts 800+ registered CAR-T clinical trials — the world's largest pipeline. Domestic CAR-T products (Relma-cel, Axicabtagene) achieve 79–90% overall response rates matching Western benchmarks at 20% of the US price.
Price
Est. from $45,000
Stay
28–42 days (in-patient)
Request free clinical review →
Paediatric OncologyPaediatric Neuroblastoma — 'Beijing Protocol'
China's 'Beijing Protocol' combining tandem ASCT, anti-GD2 monoclonal antibody and maintenance immunotherapy has lifted high-risk five-year survival rates from <30% (Southeast Asian baseline) to 70%+. Domestic GD2 antibody cuts immunotherapy maintenance costs by 60%.
Price
Est. from $35,000
Stay
6–12 months (multi-cycle)
Request free clinical review →
Endocrine OncologyMedullary Thyroid Cancer — Targeted Therapy + Telemedicine Management
RET mutation-guided vandetanib or cabozantinib therapy with quarterly telemedicine dose adjustment. Post-return follow-up via encrypted video consultation with the treating oncologist — no repeat travel required.
Price
Est. from $8,500
Stay
Ongoing (quarterly remote follow-up)
Request free clinical review →
Free case review · Reply within 24 hours
Ready to explore
your options?
Submit your medical records and a senior oncology coordinator will review your case within 24 hours — no obligation, fully confidential.
- Free case review
- Strictly confidential
- No upfront fees
- Senior oncologist review